A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Inclusion Criteria: * Male and female participants 55 to 90 years of age, inclusive, at the time of informed consent. * Participants who are residing at their current location for at least 14 days before screening and are expected to remain at the same location for the duration of the trial. * Participants with a diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association. * Participants with a Mini-Mental State Exam score of 5 to 22, inclusive, at screening and baseline visits. * Participants with onset of symptoms of agitation at least 2 weeks prior to the screening visit. * Participants with a score of ≥ 4 on the agitation/aggression item of the Neuropsychiatric Inventory-Nursing Home at the screening and baseline visits. * Participants who require pharmacotherapy for treatment of agitation per the investigator's judgment, after an evaluation for reversible factors (for example, pain, infection, polypharmacy) and a trial of nonpharmacological intervention. * Participants must have a previous magnetic resonance imaging or computed tomography of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease. Exclusion Criteria: * Participants with dementia or other memory impairment not due to Alzheimer's disease * Participants with a history of stroke, well-documented…